We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

11 hedge funds and large institutions have $571K invested in ABVC BioPharma in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

120% more funds holding

Funds holding: 5 → 11 (+6)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

2.84% less ownership

Funds ownership: 4.84% → 1.99% (-2.8%)

65% less capital invested

Capital invested by funds: $1.66M → $571K (-$1.08M)

Holders
11
Holders Change
+6
Holders Change %
+120%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$75.4K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$23.8K
3
Northern Trust
Northern Trust
Illinois
+$15.5K
4
Citadel Advisors
Citadel Advisors
Florida
+$10.6K
5
Jane Street
Jane Street
New York
+$9.56K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.16M
2
BlackRock
BlackRock
New York
-$311

ABVC Hedge Fund Activity: Q3 2022 in Review

11 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q3 2022, worth a combined $571K — down 65% from $1.66M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ABVC positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $75.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.16M sold.

  • 11 institutional investors held ABVC BioPharma (ABVC) as of Q3 2022, up from 5 in Q2 2022.
  • Funds reported $571K of ABVC BioPharma stock for Q3 2022, down 65% quarter-over-quarter.
  • 7 funds opened new ABVC BioPharma positions in Q3 2022 and 1 closed out, a net change of +6 holders.
  • The largest ABVC BioPharma buyer in Q3 2022 was Geode Capital Management, an estimated $75.4K added.
  • The largest ABVC BioPharma seller in Q3 2022 was Armistice Capital, an estimated $1.16M sold.

Based on aggregated 13F filings for Q3 2022.